Cytori Therapeutics, Inc. has extended and modified its current distribution agreement with GE Healthcare. GE has rights to sell Cytori technology in the research markets in select European markets and in the U.S. In turn, Cytori has co-exclusive sales rights to the research markets and retains primary rights to sell in all clinical markets. The term of the agreement has been extended through 2011. This agreement is specific to the Celution 800 and StemSource Systems and does not cover any ot...